Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2/3 1Phase 1 1

Status

Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Breast Neoplasms 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Melanoma 5Glioblastoma 5Carcinoma, Transitional Cell 5Ovarian Neoplasms 4Advanced Solid Tumor 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Liver Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Solid Cancer 2Small Cell Lung Cancer Extensive Stage 2Recurrence 2Neuroendocrine Tumors 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Injections 13toripalimab 12pembrolizumab 4atezolizumab 4Gemcitabine 4Carboplatin 4Cisplatin 3trastuzumab deruxtecan 2tislelizumab 2spartalizumab 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Albumin-Bound Paclitaxel 2talazoparib 1sintilimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1mirdametinib 1enfortumab vedotin 1conteltinib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Letrozole 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumor × atezolizumab × Clear all
NCT04896697 2026-05-05

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Xilio Development, Inc.

Phase 1/2 Active not recruiting
136 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05434234 2025-11-10

A Study of YL201 in Patients With Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2 Recruiting
312 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05109442 2025-08-20

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Affimed GmbH

Phase 1/2 Terminated
112 enrolled 28 charts
Other solid neoplasm

Advanced Solid Tumor

NCT04471415 2023-06-12

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Dracen Pharmaceuticals, Inc.

Phase 1/2 Terminated
61 enrolled
Other solid neoplasmThoracic

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡